LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections.

Key Points

• To evaluate the therapeutic potential of LYSG101 against staphylococcus aureus infections.
• Used a neutropenic lung infection model to assess LYSG101 efficacy.
• Administered LYSG101 and measured infection outcomes for efficacy assessment.
• LYSG101 significantly reduced infection levels compared to controls (p<0.0001).
• Demonstrated potent antibacterial activity against staphylococcus aureus in preclinical models.